ReviewJournal of innate immunity2022
Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies.
Review in Journal of innate immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Differential virulence potential of different clades of multidrug-resistantMicrobiology spectrum · 2026Article
- Immunogenic Profiling Reveals Promising RV-Identified Antigens as Vaccine Candidates AgainstInternational journal of molecular sciences · 2026Article
- GMMA as delivery system for Klebsiella pneumoniae O-antigens and K-antigens.Scientific reports · 2026Article
- Microfluidics-enabled proteomic profiling reveal iron-driven immune evasion by an antimicrobial-resistant pathogen.Cell reports methods · 2026Article
- Differential virulence potential of different clades of multidrug-resistantmedRxiv : the preprint server for health sciences · 2026Article
- Carbapenem resistance and hypervirulence iniScience · 2026Review
- <p>Molecular medicine reports · 2026Review
- Divergent humoral immune signatures in response to Klebsiella pneumoniae bacteremia.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Transfer of anti-Klebsiella pneumoniae immunity following infection in mice is protective against lethal challenge in offspring.Scientific reports · 2026Article
- Management of Diabetic Foot Infections Using Phage Therapy.Infection and drug resistance · 2026Review
- Antimicrobial Resistant Factors inInternational journal of genomics · 2026Article
- Variable progressive behavior ofFrontiers in immunology · 2026Article
- Iron metabolism contributes to virulence by enhancing serum resistance in the emerging high-risk clone ST15 CRKP.Virulence · 2025Article
- The development of functional opsonophagocytic assays to evaluate antibody responses tomSphere · 2025Article
- Dual RNA-seq analysis reveals the interaction between multidrug-resistant Klebsiella pneumoniae and host in a mouse model of pneumonia.BMC microbiology · 2025Article
- Bacteriophage treatment is effective against carbapenem-resistantAntimicrobial agents and chemotherapy · 2025Article
- Hypervirulent Klebsiella pneumoniae have better clinical outcomes than classical Klebsiella pneumoniae for lower respiratory tract infection patients.BMC microbiology · 2025Article
- Whole-genome sequencing of Klebsiella pneumoniae MDR circulating in a pediatric hospital setting: a comprehensive genome analysis of isolates from Guayaquil, Ecuador.BMC genomics · 2024Article
- Interactions and Implications ofInfection and drug resistance · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative commensal bacterium and opportunistic pathogen. In healthy individuals, the innate immune system is adept at protecting against K. pneumoniae infection. Notably, the serum complement system and phagocytic leukocytes (e.g., neutrophils) are highly effective at eliminating K. pneumoniae and thereby preventing severe disease. On the other hand, the microbe is a major cause of healthcare-associated infections, especially in individuals with underlying susceptibility factors, such as pre-existing severe illness or immune suppression. The burden of K. pneumoniae infections in hospitals is compounded by antibiotic resistance. Treatment of these infections is often difficult largely because the microbes are usually resistant to multiple antibiotics (multidrug resistant [MDR]). There are a limited number of treatment options for these infections and new therapies, and preventative measures are needed. Here, we review host defense against K. pneumoniae and discuss recent therapeutic measures and vaccine approaches directed to treat and prevent severe disease caused by MDR K. pneumoniae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.